NCT05577299

Brief Summary

The aim of the present study is to evaluate the factors affecting BAT activation in 18F-FDG-PET/CT in different tumours

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2022

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 9, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 13, 2022

Completed
19 days until next milestone

Study Start

First participant enrolled

November 1, 2022

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2025

Completed
Last Updated

October 13, 2022

Status Verified

September 1, 2022

Enrollment Period

2.8 years

First QC Date

October 9, 2022

Last Update Submit

October 9, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • the main factors that affect appearance of BAT in PET/CT studies and try to avoid these factors.

    the amount and SUV max of the detected BAT activation in PET scan correlated with the patient prognosis.

    from 7/2019 to 7/2022

Interventions

PET/CTDEVICE

18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FFDG PET/CT) is a non-invasive imaging modality used for staging and surveillance of various types of malignancies through imaging of glucose metabolism in cancer cells.

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

cancer patients undergoing PET/CT

You may qualify if:

  • This study will include all patients presented with different types of tumors.
  • patients conscious to provide informed consent

You may not qualify if:

  • Patients who have contraindications to PET/CT scanning such as: a blood glucose level higher than 150-200 mg/dL, uncontrolled diabetics.
  • Intolerance of PET/CT due to claustrophobia will be excluded from the study.
  • Patients under age of 18

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Positron Emission Tomography Computed Tomography

Intervention Hierarchy (Ancestors)

Positron-Emission TomographyTomography, Emission-ComputedImage Interpretation, Computer-AssistedDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisTomography, X-Ray ComputedMultimodal ImagingRadiographic Image EnhancementImage EnhancementPhotographyRadiographyTomography, X-RayRadionuclide ImagingTomographyDiagnostic Techniques, Radioisotope

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
resident doctor

Study Record Dates

First Submitted

October 9, 2022

First Posted

October 13, 2022

Study Start

November 1, 2022

Primary Completion

August 1, 2025

Study Completion

October 1, 2025

Last Updated

October 13, 2022

Record last verified: 2022-09